Diffuse Aggressive Histologies of Non-Hodgkin Lymphoma: Treatment and Biology of Limited Disease

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A quarter century has passed since the paradigm for treating aggressive histologies of non-Hodgkin lymphoma (NHL) presenting with limited extent of disease (LD) changed from using aggressive surgical staging techniques followed by primary radiotherapy (RT) to clinical staging followed by initial treatment with doxorubicin-containing chemotherapy (CT). This paradigm shift occurred for two reasons. First, unlike the predictable contiguous spread of Hodgkin lymphoma from one lymph node region to the next, the NHLs are largely systemic diseases characterized by early hematogenous spread. Second, the discovery of a potential curative combination of drugs, including cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), for use in advanced disease could eradicate micro-metastatic disease in patients with LD. The focus of current investigation on controlling the systemic nature of the disease has not changed. In this regard, new effective systemic therapies using combination chemotherapy plus monoclonal antibodies have resulted in improved outcome for patients with advanced disease and those treatment strategies are now under investigation in patients with LD.

Original languageEnglish (US)
Pages (from-to)207-212
Number of pages6
JournalSeminars in Hematology
Volume43
Issue number4
DOIs
StatePublished - Oct 2006

Fingerprint

Non-Hodgkin's Lymphoma
Histology
Therapeutics
Doxorubicin
Vincristine
Drug Combinations
Prednisone
Combination Drug Therapy
Hodgkin Disease
Cyclophosphamide
Radiotherapy
Lymph Nodes
Monoclonal Antibodies
Drug Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

@article{24bca79e8ad7471bb43cce731d433168,
title = "Diffuse Aggressive Histologies of Non-Hodgkin Lymphoma: Treatment and Biology of Limited Disease",
abstract = "A quarter century has passed since the paradigm for treating aggressive histologies of non-Hodgkin lymphoma (NHL) presenting with limited extent of disease (LD) changed from using aggressive surgical staging techniques followed by primary radiotherapy (RT) to clinical staging followed by initial treatment with doxorubicin-containing chemotherapy (CT). This paradigm shift occurred for two reasons. First, unlike the predictable contiguous spread of Hodgkin lymphoma from one lymph node region to the next, the NHLs are largely systemic diseases characterized by early hematogenous spread. Second, the discovery of a potential curative combination of drugs, including cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), for use in advanced disease could eradicate micro-metastatic disease in patients with LD. The focus of current investigation on controlling the systemic nature of the disease has not changed. In this regard, new effective systemic therapies using combination chemotherapy plus monoclonal antibodies have resulted in improved outcome for patients with advanced disease and those treatment strategies are now under investigation in patients with LD.",
author = "Miller, {Thomas P} and Perry, {Catherine S} and Rimsza, {Lisa M}",
year = "2006",
month = "10",
doi = "10.1053/j.seminhematol.2006.07.001",
language = "English (US)",
volume = "43",
pages = "207--212",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Diffuse Aggressive Histologies of Non-Hodgkin Lymphoma

T2 - Treatment and Biology of Limited Disease

AU - Miller, Thomas P

AU - Perry, Catherine S

AU - Rimsza, Lisa M

PY - 2006/10

Y1 - 2006/10

N2 - A quarter century has passed since the paradigm for treating aggressive histologies of non-Hodgkin lymphoma (NHL) presenting with limited extent of disease (LD) changed from using aggressive surgical staging techniques followed by primary radiotherapy (RT) to clinical staging followed by initial treatment with doxorubicin-containing chemotherapy (CT). This paradigm shift occurred for two reasons. First, unlike the predictable contiguous spread of Hodgkin lymphoma from one lymph node region to the next, the NHLs are largely systemic diseases characterized by early hematogenous spread. Second, the discovery of a potential curative combination of drugs, including cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), for use in advanced disease could eradicate micro-metastatic disease in patients with LD. The focus of current investigation on controlling the systemic nature of the disease has not changed. In this regard, new effective systemic therapies using combination chemotherapy plus monoclonal antibodies have resulted in improved outcome for patients with advanced disease and those treatment strategies are now under investigation in patients with LD.

AB - A quarter century has passed since the paradigm for treating aggressive histologies of non-Hodgkin lymphoma (NHL) presenting with limited extent of disease (LD) changed from using aggressive surgical staging techniques followed by primary radiotherapy (RT) to clinical staging followed by initial treatment with doxorubicin-containing chemotherapy (CT). This paradigm shift occurred for two reasons. First, unlike the predictable contiguous spread of Hodgkin lymphoma from one lymph node region to the next, the NHLs are largely systemic diseases characterized by early hematogenous spread. Second, the discovery of a potential curative combination of drugs, including cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), for use in advanced disease could eradicate micro-metastatic disease in patients with LD. The focus of current investigation on controlling the systemic nature of the disease has not changed. In this regard, new effective systemic therapies using combination chemotherapy plus monoclonal antibodies have resulted in improved outcome for patients with advanced disease and those treatment strategies are now under investigation in patients with LD.

UR - http://www.scopus.com/inward/record.url?scp=33749262192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749262192&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2006.07.001

DO - 10.1053/j.seminhematol.2006.07.001

M3 - Article

C2 - 17027654

AN - SCOPUS:33749262192

VL - 43

SP - 207

EP - 212

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 4

ER -